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and Computer Science, and kDepartment of Physics, University of Michigan, Ann Arbor, MichiganABSTRACT Type II diabetes, in its late stages, is often associated with the formation of extracellular islet amyloid deposits
composed of islet amyloid polypeptide (IAPP or amylin). IAPP is stored before secretion at millimolar concentrations within
secretory granules inside the b-cells. Of interest, at these same concentrations in vitro, IAPP rapidly aggregates and forms fibrils,
yet within secretory granules of healthy individuals, IAPP does not fibrillize. Insulin is also stored within the secretory granules
before secretion, and has been shown in vitro to inhibit IAPP fibril formation. Because of insulin’s inhibitory effect on IAPP fibril-
lization, it has been suggested that insulin may also inhibit IAPP-mediated permeabilization of the b-cell plasma membrane
in vivo. We show that although insulin is effective at preventing fiber-dependent membrane disruption, it is not effective at stop-
ping the initial phase of membrane disruption before fibrillogenesis, and does not prevent the formation of small IAPP oligomers
on the membrane. These results suggest that insulin has a more complicated role in inhibiting IAPP fibrillogenesis, and that other
factors, such as the low pH of the secretory granule, may also play a role.INTRODUCTIONAlthough the exact cause of b-cell death in Type II diabetes
is unknown, there is strong evidence that human islet
amyloid polypeptide (IAPP) plays an important role (1–3).
It is well known through in vitro, tissue culture, and trans-
genic animal studies, as well as postmortem clinical exam-
inations, that large b-sheet aggregates of IAPP, known as
islet amyloid, are often associated with the development
of Type II diabetes (1–3). Similar extracellular proteina-
ceous deposits composed of large aggregates of proteins
in a characteristic cross b-sheet conformation are being
found in a growing number of pathologies, including
Alzheimer’s, Huntington’s, and Parkinson’s disease among
many others (4). An aggregated (but not necessarily
fibrillar) form of the peptides and proteins implicated
in these amyloid-associated diseases has been found to
disrupt the integrity of cellular membranes to various
degrees by allowing the uncontrolled influx of ions (in
particular calcium) into the cell and subjecting the cell to
membrane-associated stress (5,6).
The relevant factors that trigger IAPP aggregation and
pancreatic b-cell membrane disruption in some individuals
but not others are elusive, as the pathology of IAPP aggre-
gation occurs most often with the wild-type peptide and is
not associated with mutations of the IAPP sequence, except
for the rare S20G polymorphism (7–10). Because wild-type
IAPP is both aggressively amyloidogenic and toxic at low
concentrations (<1 mM) when it is added exogenously, yet
is stored in the secretory granule of b-cells at concentrationsSubmitted June 10, 2010, and accepted for publication September 27, 2010.
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dysfunction in nondiabetic individuals, it is unknown how
IAPP is regulated to prevent both its aggregation and its
inherent cytotoxicity. In fact, considering the high toxicity
of IAPP in vitro, it may be more relevant to question
what stops IAPP from permeabilizing b-cells in healthy
individuals, rather than what triggers IAPP-induced toxicity
to b-cells in diabetics.
Insulin, which is copackaged and cosecreted with IAPP
within the secretory granule, has emerged as a possible
regulator of IAPP fibrillogenesis. Insulin forms heterocom-
plexes with IAPP (11–13). Several studies have reported
that these heterocomplexes can inhibit IAPP amyloid forma-
tion (12–15,17–20,22), although there is also evidence for
either little change or a slight increase in the rate of fibril
formation at lower ratios of IAPP to insulin (23). Because
insulin suppresses IAPP amyloid fiber formation and is
found in great excess over IAPP in the secretory granule,
it is frequently assumed that insulin also inhibits the
inherent toxicity of IAPP (11,14,18). However, studies on
other amyloid inhibitors have shown that these two actions
are not necessarily linked. For instance, compounds that
bind to the end-stage of aggregation and consist mostly of
amyloid fibrils are frequently unsuccessful in reducing the
toxicity of amyloidogenic proteins, most likely due to the
low toxicity of the end-stage amyloid fibers (24). A prime
example of this effect is the anti-amyloid-b1-11 antibody,
which was shown to inhibit amyloid-b1–42 fibrillization
yet failed to prevent amyloid-b1–42 toxicity (25). Other
compounds have been shown to actually increase the
toxicity of amyloid proteins by inhibiting the formation of
the relatively inert amyloid fibrils while increasing the
amount of peptide in the small oligomeric, more toxicdoi: 10.1016/j.bpj.2010.09.070
686 Brender et al.form. An example of this effect is clusterin (apolipoprotein
J), a protein found in Alzheimer’s disease plaques that
inhibits Ab1–42 from forming amyloid yet increases the
cytotoxicity of the Ab1–42 peptide (26–28). Conversely,
other inhibitors have been shown to block the toxicity of
these peptides without affecting or increasing amyloid
formation. In this study, we show that insulin does not
suppress the ability of IAPP to cause model membrane
disruption, an effect that is believed to be one of the prime
indicators of IAPP toxicity, in a simple manner. Instead,
insulin appears to eliminate only later fiber-dependent
membrane disruption, without affecting earlier events in
the membrane permeabilization process.MATERIALS AND METHODS
IAPP and insulin preparation
Human IAPP was purchased from Anaspec (San Jose, CA). Recombinant
human insulin expressed in yeast was purchased from Sigma-Aldrich
(St. Louis, MO). The IAPP peptide used in this study was amidated at
the C-terminus like the natural peptide. Preformed aggregates in both
peptide preparations were disaggregated by first dissolving the peptide in
a 75% acetonitrile/water solution at a concentration of 1 mg/mL. The
peptides were then lyophilized and the lyophilized powder was redissolved
in hexafluoroisopropanol (HFIP) at a concentration of 2–4 mg/mL. The
HFIP was removed by lyophilization overnight at high vacuum (29). After
lyophilization was completed, the peptide was first dissolved in pure water
to a concentration of 25 mM in siliconized Eppendorf tubes and then diluted
with 2 buffer to create the final working solution (final buffer composi-
tion: 10 mM sodium phosphate, pH 7.4, 100 mM NaCl) (30).Liposome preparation
1-Palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (POPG) and
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) dissolved in
chloroform were purchased from Avanti (Alabaster, AL). To make lipo-
somes, chloroform lipid stocks were dried with a stream of nitrogen and
then placed under vacuum overnight to remove residual solvent. The lipid
films were then rehydrated for 1–2 h with 10 mMNaPi buffer at pH 7.4 con-
taining 100 mM NaCl. The rehydrated lipids were vortexed and then sub-
jected to eight freeze-thaw cycles. The resulting multilamellar vesicles
were extruded 21 times through two 100 nm polycarbonate Nucleopore
membrane filters (Whatman) to create unilamellar vesicles.
To prepare liposomes with dye encapsulated inside, we created vesicles
as above except that the buffer also contained 50 mM 5(6)-carboxyfluores-
cein. Free dye was separated from the dye-encapsulated lipid vesicles by
running the sample through a 10 mL Sephadex G-50 gel filtration column
(Sigma-Aldrich). Lipid concentrations were determined using the Stewart
method (31). Liposomes with encapsulated dye were mixed with liposomes
without dye in a 1:20 ratio to create the final stock solution.Dye leakage experiments with direct addition
of IAPP/insulin samples
IAPP (10 mM concentration) was directly mixed with 200 mMPOPG/POPC
liposomes (1:1 molar ratio) in 50 mM sodium phosphate buffer pH 7.4,
100 mM NaCl. The fluorescence was then recorded using a Biotek Synergy
2 plate reader equipped with 494 nm excitation filter with a 2 nm bandpass,
and a 512 nm emission filter with a 2 nm bandpass for 400 min at 25C
under fast shaking.Biophysical Journal 100(3) 685–692The fluorescence signal recorded was normalized against the value at
100% permeabilization by adding Triton-X detergent to 0.2% v/v after
400 min, which effectively permeabilized any remaining intact dye-encap-
sulated large unilamellar vesicles (LUVs). Dye leakage was plotted accord-
ing to the following equation:
Dye leakage ¼ FsampleðtÞ  Fbaseline
Fdetergent  Fbaseline :
Dye leakage experiments with preincubation
of IAPP/insulin
IAPP or IAPP/insulin was preincubated for the indicated length of time at
a 25 mM concentration in siliconized Eppendorf tubes at 25C without
shaking, and then diluted and added to a concentrated POPG vesicle stock
solution to initiate membrane permeabilization. The final concentrations for
the assay were 1 mM IAPP, 200 mM POPG, and 0, 1, or 10 mM insulin.Thioflavin T assay
Peptides were initially solubilized with deionized water. Buffer and Thiofla-
vin T (ThT) were then added to make the final concentrations 5 mM ThT,
25 mM IAPP, and 25 or 250 mM insulin in 100 mM NaCl, 10 mM NaPi,
pH 7.4 buffer. The aggregation reaction was performed without shaking
in sealed Corning 96-well, clear-bottom, half-area, nonbinding surface
plates at a constant temperature of 25C. The fluorescence from the ThT
reporter dye was recorded by a Biotek Synergy 2 plate reader using
a 440 excitation filter equipped with a 30 nm bandpass, and a 485 emission
filter with a 20 nm bandpass.Glutaraldehyde cross-linking and Western
blotting
IAPP (25 mM) and IAPP/insulin (25 mM: 25 mM) were incubated at room
temperature with POPG/POPC LUVs (1:1 molar ratio, 200 mM) in 100 mM
NaF, 10 mM NaPi, pH 7.4, in siliconized Eppendorf tubes at 25C without
shaking. After incubation, 0.01% (v/v) glutaraldehyde was added to initiate
cross-linking at each time point. The cross-linking reaction was allowed to
continue for 30 min and was then quenched by the addition of 100 mM
lysine. Then, 3 sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) loading buffer was added and the samples were placed
on a heat block at 90C for 2 min. The samples were electrophoresed on
10–20% (w/v) polyacrylamide SDS Tris-Tricine Ready Gel (Bio-Rad,
Hercules, CA), transferred with CAPs transfer buffer, pH 11.0, immuno-
blotted on nitrocellulose with rabbit polyclonal a-IAPP antibody (Anaspec,
San Jose, CA). The primary antibody was visualized with a horseradish
peroxidase conjugated a-rabbit antibody and enhanced chemiluminescence
(Bio-Rad, Hercules, CA).RESULTS
The kinetics of membrane disruption by IAPP
in the absence of insulin is biphasic, and the
second phase is associated with the maturation
of IAPP amyloid fibrils
One of the primary mechanisms of IAPP-induced toxicity is
believed to be disruption of the cellular membrane (5,6,32–
38), which leads to dysregulation of calcium homeostasis,
mitochondrial overload, and eventually apoptosis. We used
Effect of Insulin on IAPP Membrane Disruption 687a dye leakage assay to measure the ability of IAPP to per-
meabilize model membranes. A self-quenching dye, (6)-car-
boxyfluorescein, was entrapped at high concentrations in
POPC/POPG vesicles (1:1 molar ratio, 200 mM lipid
concentration) and incubated with either IAPP alone or
IAPP with varying concentrations of insulin. Disruption of
the integrity of the membrane surface releases the vesicle
contents into solution, where dilution of the self-quenching
dye results in a large increase in fluorescence.
A time-trace of dye leakage induced by 10 mM IAPP is
shown in Fig. 1. In the absence of insulin, membrane perme-
abilization by IAPP occurs in two distinct stages. Typically,
membrane-disrupting agents (e.g., antimicrobial peptides)
cause rapid, near-exponential increases in fluorescence as
transient pores form on the membrane (39,40). The final
normalized fluorescence value as t/N may not approach
one, as would be expected for total disruption of all vesicles
(graded leakage). This phenomenon has been observed for
antimicrobial peptides and reported for IAPP (38), and is
believed to result from a relaxation process that relieves
mechanical stress on the membrane, resulting in mass
imbalance on the outer leaflet of the membrane caused by
the binding of the peptide (41). Several mechanisms have
been proposed for the relaxation process, including translo-
cation of the peptide across the membrane (42,43), which
may occur through the formation of toroidal pores (44) or
by the removal of IAPP-lipid adducts from the membrane
(33,36,45,46).
The early stage of membrane disruption by IAPP (t¼ 0 to
~50 min) indeed displays the double exponential kinetics
that is typical of antimicrobial peptides (Fig. 1, dashed
line) and readily apparent on this timescale, with the initial
rise in fluorescence followed by the gradual decrease in the
rate-of-efflux from the vesicle. However, a second phase is
also apparent after ~50 min in which the fluorescence begins
to rise once again, as shown in Fig. 1. This second phase hasFIGURE 1 Mean (n ¼ 5) kinetic trace of membrane disruption of 10 mM
IAPP added to 200 mM POPG/POPC vesicles (1:1 molar ratio). The initial
phase (t ¼ 0–50 min) of membrane disruption was fit to a double exponen-
tial curve: Vesicles were stable over the time course of the experiment in the
absence of IAPP, as shown by the negligible dye leakage that occurred in
control liposomes.been linked to damage to the membrane through the growth
of amyloid fibers on the membrane, because the kinetic
profile of the second phase of dye leakage is consistent
with the kinetic profile of amyloid formation (see Fig. 3),
as previously shown for IAPP (33). The fitted curve is the
same for both Figs. 1 and 2.Insulin blocks late fibril-dependent membrane
disruption but not initial membrane
permeabilization by IAPP
If fibril formation correlates with the later phase of
membrane disruption, molecules that block fibril formation
should also inhibit or block membrane permeabilization.
Because insulin has been shown to block fibril formation
in both aqueous and membrane environments (14–20), it
is likely that it will also block fibril-dependent membraneFIGURE 2 (A) Mean (n ¼ 5) kinetic traces of membrane disruption
by IAPP/insulin mixtures. The double exponential fit to the initial
(t ¼ 0–50 min) phase of membrane disruption by IAPP alone is shown
for comparison (dashed line, ðdashed line; dye leakage ¼ 0:16662þ
0:11203  ð1 et=143:3Þ þ 0:08171  ð1 et=12:82ÞÞ). Insulin by itself
did cause membrane disruption at any concentration over the course of
the experiment (data for 5, 10, and 50 mM insulin not shown). (B)
Membrane disruption caused by IAPP/insulin mixtures at t¼ 50 min. Error
bars indicate mean 5 SE (n ¼ 5). (C) Membrane disruption caused by
IAPP/insulin mixtures at t ¼ 600 min. Error bars indicate mean 5 SE
(n ¼ 5).
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of insulin (2:1 IAPP/insulin molar ratio) block the second
phase of membrane disruption. The total amount of
membrane disruption in the presence of insulin is similar
to that expected based on a model of the first phase alone
(Fig. 3 B), a strong indication that suppression of IAPP
amyloid formation by insulin also eliminates damage to
the membrane associated with the amyloid formation
process. This is in agreement with previous results that
showed a decrease in the total membrane leakage by IAPP
in 7:3 POPC/POPS liposomes after 1000 min in the pres-
ence of insulin (33).
Of interest, although the second phase of membrane
disruption is blocked, the initial rise in fluorescence is
almost entirely unaffected by insulin (insulin by itself only
negligibly affects the stability of the dye-loaded vesicles).
For this lipid composition, insulin apparently does not block
association of IAPP with the membrane, in agreement with
previous attenuated total reflectance Fourier transform
infrared (ATR-FTIR) results that showed a reduced, but still
substantial, attachment of IAPP in 7:3 POPC/POPS lipo-
somes in the presence of insulin (20). In addition, once it
is bound to the membrane, IAPP apparently is still able to
affect membrane disruption.Insulin slows the time-dependent decrease in
the ability of IAPP to cause membrane disruption
associated with the formation of amyloid fibrils
in solution
The varying ability of different oligomeric forms of amyloid
proteins to cause membrane disruption has been the subjectFIGURE 3 Amyloid fiber formation in relation to the second phase of
membrane disruption. Amyloid fiber formation by 10 mM IAPP and
10 mM IAPP/5 mM insulin as tracked by ThT fluorescence is plotted on
the left axis, and the second phase of membrane disruption is plotted
on the right axis. The second phase of membrane disruption was defined
as the difference between the observed fluorescence values and those pre-
dicted by a double exponential fit of the first 50 min (see Fig. 1). Higher
concentrations of insulin led to high background signals of THT fluores-
cence, possibly due to nonspecific binding of THT to nonamyloid forms
of insulin (data not shown).
Biophysical Journal 100(3) 685–692of intensive research. Although the exact toxicity of partic-
ular oligomeric species has been the subject of much contro-
versy, mature amyloid fibrils that are fully preformed in
solution before addition to the membrane have been found
almost universally to be less damaging to the membrane
than oligomeric forms of the same peptides. For this reason,
some investigators have hypothesized that the formation of
amyloid fibrils serves as a protective mechanism against the
toxic effects of smaller oligomeric species (47).
Because the amyloid form of the peptide is less effective
at disrupting membranes than the freshly dissolved peptide,
the ability of IAPP to permeabilize membranes declines
with incubation time in solution before addition to the
membrane as the percentage of preformed amyloid in the
sample increases. We monitored this effect by adding
IAPP (with or without insulin) to fresh lipid preparations
at each time point to measure how membrane disruption
changed with the growth of amyloid fibrils (Fig. 4). IAPP’s
ability to permeabilize liposomes in the absence of insulin
declined rapidly after 5 h of preincubation in solution before
it was added to the liposomes, which roughly corresponds
with the start of exponential fibril growth in solution
measured by ThT fluorescence at ~15 h (Fig. 4 B). This
result is in agreement with numerous reports that have
shown mature IAPP amyloid fibrils to be nondisruptive to
membranes and nontoxic to cells, in contrast to earlier forms
of the peptide.
In contrast to the rapid decrease in permeabilization
activity with preincubation time in the absence of insulin,
the ability of the IAPP/insulin mixture to permeabilize lipo-
somes declined only a little over the course of the experi-
ment. The membrane disruptive activity of 1:1 IAPP/
insulin did not fully disappear until after ~50 h, when it
started to slowly polymerize (Fig. 4 B). At a higher concen-
tration of 250 mM (10 the equimolar concentration to
IAPP), insulin completely prevented the time-dependent
decrease in permeabilization over the course of the experi-
ment. Insulin by itself did not cause membrane disruption
over the course of the experiment.Insulin does not prevent the formation of small
oligomeric species of IAPP
We performed glutaraldehyde cross-linking to detect popu-
lations of small oligomeric species of IAPP bound to the
membrane at several time points (at 0, 2, 3, and 4 h) during
membrane-catalyzed aggregation of IAPP, using an IAPP-
specific antibody to identify IAPP species. In the absence
of insulin, we detected bands that corresponded to mono-
mers, dimers, trimers, and tetramers, along with a strong
band that was identified as a high molecular weight (MW)
species that exceeded the resolving power of gel. Over
time, we were able to detect a decrease in the intensity of
the monomer band and a corresponding increase in the olig-
omer bands by comparing the relative intensities of bands
FIGURE 4 (A) Time course of membrane
disruption by IAPP preincubated with insulin.
First, 25 mM IAPP were incubated in solution
with 0, 25, or 250 mM insulin in the absence of
lipids for the indicated time points. A 1:25 dilution
(1 mM IAPP and 0, 1, or 10 mM insulin) was then
added to 200 mM POPG vesicles and the dye
leakage that was induced after 100 s was recorded.
(B) Amyloid fiber formation by 25 mM IAPP incu-
bated with 0, 25, or 250 mM insulin in the absence
of lipids as shown by ThT fluorescence.
Effect of Insulin on IAPP Membrane Disruption 689from the initial time point (lane 1) and later time points
(lanes 2–4), indicating time-dependent aggregation. Of
interest, an equimolar amount of insulin only inhibited the
formation of the high-MW species near the top of the gel,
and showed little to no ability to block the formation of
the small oligomeric species of IAPP in the IAPP/insulin
sample (lanes 5–8 in Fig. 5). To summarize, insulin blocks
fibril formation, but is ineffective at blocking the formation
of small membrane-active oligomers, and can actually
increase membrane disruption in some circumstances by
suppressing the tendency of IAPP to form membrane-inert
amyloid fibers when IAPP is incubated in solution before
being bound to the membrane.DISCUSSION
Although insulin has been demonstrated to be an in vitro
inhibitor of IAPP fibrillization, its effects on IAPP
membrane disruption and toxicity are less understood. To
test the impact of insulin on IAPP toxicity, we observedFIGURE 5 Cross-linking of IAPP and insulin bound to POPG/POPC
LUVs. IAPP (25 mM) or IAPP/insulin (25 mM/25 mM) was incubated
with POPG/POPC vesicles (1:1 molar ratio, 200 mM) at room temperature
for the indicated time points. At each time point, aliquots of each sample
were removed and cross-linked with 0.01% (v/v) glutaraldehyde. The reac-
tions were quenched with the addition of lysine and loading buffer, boiled,
and separated by SDS-PAGE. The gel was transferred and then immuno-
blotted with a rabbit polyclonal a-IAPP antibody.the ability of insulin to inhibit IAPP fibril formation, as
well as IAPP’s ability to disrupt model membranes under
buffer conditions that approximate the pH and ionic strength
found after secretion. We found that in POPC/POPG
vesicles, 1), insulin does not inhibit the rapid permeabiliza-
tion that occurs immediately after addition of IAPP to
membranes; 2), insulin blocks the later rise in membrane
permeabilization that is associated with fiber formation;
3), insulin only inhibits amyloid fibrillization, and not
the formation of small oligomeric species of IAPP on
the membrane; 4), the ability of IAPP to permeabilize
membranes decreases rapidly with the time the peptide is
incubated in solution in the absence of membranes; and
4), insulin arrests the time-dependent decrease in permeabi-
lization activity, and actually maintains IAPP in such a state
that it is able to permeabilize liposomes for a far longer
period of time.
Membrane disruption is believed to be one of the primary
causes of cell death caused by amyloidogenic proteins
(32,37,48). Although there is very strong evidence that
hIAPP has a deleterious effect on cell membranes, the
molecular mechanisms by which this occurs are not under-
stood. Studies so far have been conflicting: some have
provided evidence for the in vitro formation of discrete
ion-channel-like pores, whereas others have provided
evidence for the total disruption of the bilayer through
membrane fragmentation. Strong evidence for nonspecific
membrane disruption through fibril growth at the membrane
comes from Engel et al. (33), who showed that the time
course of calcein leakage from vesicles was strongly corre-
lated with amyloid fibril formation, and that the kinetics of
dye-leakage could be strongly altered by seeding amyloid
formation, implying a direct link between fibril formation
and membrane disruption. Furthermore, electron micro-
graphs of giant unilamellar vesicles in the presence of
IAPP showed the vesicles to be severely distorted (33), indi-
cating that membrane permeabilization occurs nonspecifi-
cally by mechanical fragmentation of the membrane, as
has been observed in other studies (36,45,46). On the other
hand, channel-like structures have also been observed in
membranes by atomic force microscopy, and discrete elec-
trical conductances suggestive of channels have been
recorded that could be reversibly blocked by zinc and otherBiophysical Journal 100(3) 685–692
690 Brender et al.ligands (35,49,50). In addition, a fragment of IAPP com-
prising the putative membrane active domain caused a
rapid rise in intracellular calcium when added to islet cells,
but did not form amyloid fibrils when bound to the
membrane (6,51,52). It is difficult to account for these
findings with the membrane-damage-through-fibril-growth
model alone, suggesting a role for nonfibril-dependent
membrane damage in the early stages of membrane disrup-
tion. Indeed, early membrane permeabilization events were
observed in the study by Engel et al. (33), albeit with
a smaller degree of disruption compared with our findings
(~10% vs. ~30). This difference is most probably due to
the higher anionic content of the vesicles used here (50%
vs. 30%), and their use of calcein (MW 622.6) versus car-
boxyfluorescein (MW 376.3), which permits leakage
through smaller pores. It is likely that both channel-like
and nonspecific peremabilization occurs when IAPP is
added to membranes, with the amount of each being depen-
dent on other factors such as the IAPP concentration and
lipid environment, as has been proposed for the related
Ab peptide (53). In particular, the ratio of disruption in
the early- to late-phase disruption has been shown to depend
on the ratio of charged to zwitterionic lipids in binary
POPC/POPS mixtures, with the fiber-dependent late-phase
disruption dominating at the low charged to zwitterionic
ratios typical of cells (33,35). Channel-like activity has
also been shown to be diminished in the presence of choles-
terol (3,5). On the other hand, in more complex raft-like
lipid mixtures, complete disruption of the membrane
occurred immediately upon addition of IAPP, even in
the absence of anionic lipids and despite a much slower
fibrillization rate in comparison with mixed POPC/POPS
membranes (54).
Insulin was found to inhibit only the later fibril-dependent
process, in agreement with a study by Larson and Miranker
(14) that showed that insulin strongly inhibits the elongation
step of monomer addition to existing fibrils at substoichio-
metric concentrations. This inhibition of the elongation
process can be expected to strongly affect membrane disrup-
tion through mechanical stress caused by fiber growth at the
membrane. On the other hand, the lack of effect on the
initial membrane permeabilization activity is consistent
with ATR-FTIR studies showing that insulin does not
completely suppress the binding of IAPP to 7:3 POPC/
POPS liposomes (20). The initial rise in membrane perme-
abilization could be linked to formation of channel-type
structures; however, definite identification is inconclusive
and outside the scope of this study.
Among amyloid peptides, IAPP is somewhat unusual in
that the highest amount of membrane disruption is detected
immediately after solubilization and then decreases mono-
tonically (Fig. 4) (55,56). This is in contrast to most other
amyloid proteins, in which membrane disruption first
increases with time, as toxic membrane-binding oligomers
form in solution, and then decreases as the protofibrillarBiophysical Journal 100(3) 685–692species are converted into relatively inert mature amyloid
fibrils (57–66). The transient nature of the protofibrillar
species limits the amount of time the b-cell is exposed to
the highly toxic IAPP species, because IAPP either diffuses
away from the secretion point, where it rapidly disassociates
below nonaggregating concentrations, or is sequestered in
less toxic amyloid fibrils (38,67–69).
In the act of blocking IAPP fibril formation, insulin actu-
ally prolonged the lifetime of membrane-damaging IAPP
species long past its normal span in the absence of insulin
(Fig. 4). In the absence of insulin, IAPP formed fibrils in
solution, and the ability of IAPP to cause membrane disrup-
tion was rapidly reduced after 5 h (Fig. 4). However, in the
presence of an equimolar amount of insulin, the ability of
IAPP to induce membrane disruption was maintained for
far longer and only decreased slowly after ~50 h (Fig. 4).
The ability of insulin to suppress the formation of high-
MW species of IAPP, but not small oligomers of IAPP on
the membrane, was confirmed by time-lapse cross-linking
of IAPP and IAPP/insulin solutions added to POPG/POPC
liposomes. Small oligomers could be detected in both
samples regardless of whether insulin was present with
IAPP. The IAPP monomer quickly disappeared in the
sample without insulin, aggregating to larger oligomeric
species that were trapped at the top of the gel, and were
not seen when IAPP was coincubated with insulin
(Fig. 5). Of note, the bands appeared in the same MW range
regardless of the presence of insulin, indicating that insulin
did not form efficient heterocomplexes with IAPP in the
lipid environment under these experimental conditions.
It is notoriously difficult to extrapolate from results on
model systems to the in vivo situation, especially for a
system as complex as IAPP/insulin/membrane. Taking
these difficulties into consideration, it is worthwhile to
consider what other factors besides insulin may be respon-
sible for maintaining IAPP in a nontoxic state in normal
individuals in the secretory granule and immediately after
secretion. The anionic content of the membrane, which is
known to change in type II diabetics (70), is likely to be
an important factor (71). The changes in membrane choles-
terol and free fatty acid levels that occur in the development
of type II diabetes have been shown to have a complex effect
on Ab toxicity (72). Preliminary results suggest that a
similar effect may exist for IAPP as well (35,54,73). Of
significance, hIAPP transgenic mice only develop symp-
toms of diabetes when fed a high-fat diet (74), indicating
a possible role of lipid metabolism in the etiology of IAPP
in type II diabetes. An additional important factor may be
the acidic pH of the vesicle. Acidic pH is known to strongly
inhibit the fibrillogenesis of the IAPP peptide (75,76), and
an acidic pH has been shown to significantly reduce the
amount of membrane disruption by fragments of the IAPP
peptide by altering the position of IAPP fragment within
the membrane, causing it to occupy a more surface-associ-
ated topology than it would at neutral pH (6,52). Other
Effect of Insulin on IAPP Membrane Disruption 691contents of the b-cell secretory granule, such as zinc, which
has been shown to reversibly blockade IAPP channels, may
suppress the remaining disruptive activity that is unaffected
by insulin (50). Further work is needed, particularly in live-
cell systems, to clarify these matters.
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